- Company
- 20-valent pneumococcal conjugate vaccine to enter market
- by Whang, byung-woo Nov 8, 2024 05:47am
- The pneumococcal vaccine market, which has shifted with the introduction of a 15-valent vaccine this year, is expected to again face fierce competition with the approval of a new 20-valent vaccine. Pfizer, which is about to launch a new product, plans to replace the share of its existing product, Prevenar 13 with its new product, Prevenar 20
- Company
- Optivo's clinical results for Koreans with gastric cancer
- by Son, Hyung Min Nov 8, 2024 05:47am
- Optivo, an immunotherapy used to treat certain types of cancer, showed a positive result in gastric cancer clinical trials that involved Koreans. The study demonstrated a 47% reduction in the disease progression and death risk compared to conventional therapies. According to industry sources on November 6th, Bristol Myers Squibb (BMS) and
- Company
- Geo-Young and UBC Korea sign MOU to distribute Bimzelx
- by Son, Hyung Min Nov 8, 2024 05:47am
- Geo-Young announced today that it has signed a Memorandum of Understanding with UBC Korea to distribute Bimzelx. Under the agreement, Geo-Young will carry out the entire distribution process from storage to supply of Bimzelx. Bimzelx is a treatment for plaque psoriasis that simultaneously and directly targets and inhibits interleukin
- Opinion
- [Reporter's View] Regarding the obesity drug craze
- by Son, Hyung Min Nov 8, 2024 05:46am
- There is one research and development item that is gaining explosive popularity among both global and domestic pharmaceutical companies &8211;obesity treatment. The use of obesity drugs has also increased dramatically with the significant rise in the number of obese people around the world. Global sales of obesity drugs reached USD 6.68
- Company
- Novo Nordisk tops KRW 14T in sales, thanks to Wegovy
- by Whang, byung-woo Nov 8, 2024 05:46am
- Novo Nordisk has recorded a strong sales performance in Q3, driven by the steady growth of its major products, including Wegovy and Ozempic. According to Novo Nordisk's business reports on November 6th (local time), they recorded US$10.267 billion (KRW 14.3378 trillion) in Q3 sales, up 21% from the previous year. Its operating profit a
- Company
- Oral psoriasis drug 'Sotyktu' lands at Big 5 hospitals
- by Son, Hyung Min Nov 8, 2024 05:46am
- Oral psoriasis drug 'Sotyktu' is now available for prescription at tertiary general hospitals. According to industry sources, BMS Korea’s TYK2 inhibitor, Sotyktu (deucravacitinib), has passed the drug committees of the 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul St. Mary's Hospital, Seoul
- Policy
- Drug switching for atopic dermatitis measure submitted
- by Lee, Tak-Sun Nov 7, 2024 05:47am
- Discussions about allowing drug switching between biological agents and JAK inhibitors used to treat severe atopic dermatitis are speeding up. The Health Insurance Review and Assessment Service (HIRA) has already prepared the reimbursement criteria, and pharmaceutical companies have submitted their measures for voluntary drug price redu
- Company
- Reimb discussions discontinued for NMOSD drug Uplizna
- by Eo, Yun-Ho Nov 7, 2024 05:47am
- Uplizna, a new drug for neuromyelitis optica spectrum disorder (NMOSD) that is administered twice a year, has failed to pass the final gateway to reimbursement in Korea. According to Dailypharm coverage, Mitsubishi Tanabe Pharma Korea’s pricing negotiations with the National Health Insurance Service (NHIS) for Uplizna (inebilizumab), a t
- Product
- KTIC, ’21s Wegovy prescriptions, not a telemedicine issue'
- by Kang, Hye-Kyung Nov 7, 2024 05:47am
- the platform industry has spoken out to state its opinion regarding the government’s move to restrict non-face-to-face prescriptions in response to the criticism that 'obesity drugs are being easily prescribed &8211; just in 21 seconds - through non-face-to-face medical treatment platforms.’ While the platform industry sympathizes with
- Policy
- Novartis cuts price of Cosentyx after PVA negotiations
- by Lee, Tak-Sun Nov 7, 2024 05:46am
- The price of Novartis’s Cosentyx(secukinumab) is set to be reduced due to its increased use. This is because the National Health Insurance Service recently reached an agreement during Price-Volume Agreement negotiations with the company for Cosentyx. According to industry sources on the 6th, the insurance price ceiling of Cosentyx wa
